Semaglutide Injection Sites: Safe Techniques & Clinical Guidance

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is administered via subcutaneous injection into specific anatomical sites: the abdomen, thigh, or upper arm. Proper site selection, injection depth, and consistent rotation patterns are essential to minimize lipohypertrophy, ensure uniform drug absorption, and reduce injection-site reactions.

Safe injection technique is foundational to treatment success, but it is only one component of a comprehensive care plan. Understanding your individual response patterns, supported by clinical guidance and potentially informed by genetic predispositions in GLP-1 pathways, can help optimize both safety and efficacy.

Approved Subcutaneous Injection Sites and Anatomical Landmarks

The FDA-approved injection sites for semaglutide are the subcutaneous tissue of the abdomen, thigh, and upper arm. Each site offers distinct advantages: abdominal injections typically allow easier self-administration and consistent depth control, while thigh and arm sites provide alternative rotation options to reduce localized tissue stress.

The subcutaneous layer lies between the epidermis and muscle, typically 5–10 mm deep depending on body composition. Injecting at the correct depth ensures medication reaches the subcutaneous space where absorption is most predictable and side effects are minimized.

Injection Site Rotation Strategy and Lipohypertrophy Prevention

Rotating injection sites each week is a critical practice to prevent lipohypertrophy—abnormal fat tissue thickening that can impair drug absorption and create unsightly lumps. A structured rotation pattern ensures no single area is overused within a 4-week cycle.

Rotation Week	Recommended Site	Specific Area
Week 1	Abdomen	Right side, 2 inches from navel
Week 2	Abdomen	Left side, 2 inches from navel
Week 3	Thigh	Outer surface, mid-thigh region
Week 4	Upper Arm	Back of arm, midway between shoulder and elbow

Technique Considerations: Needle Depth, Angle, and Consistency

Standard semaglutide pens use 29–31 gauge needles inserted at a 90-degree angle to the skin. Holding the needle for 6–10 seconds after full plunger depression ensures complete medication delivery and reduces backflow into the skin.

Maintaining consistent injection technique—same angle, insertion speed, and hold duration—promotes predictable absorption kinetics. Variability in technique can lead to inconsistent drug levels and treatment response, making standardization important for optimal outcomes.

Safety Monitoring, Contraindications, and When to Seek Provider Guidance

Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use semaglutide. A qualified healthcare provider must assess eligibility, screen for contraindications, and establish baseline parameters before treatment initiation.

Common injection-site reactions include redness, bruising, or mild discomfort that typically resolve within hours. However, persistent pain, spreading erythema, warmth, or signs of infection warrant immediate provider contact. Regular monitoring ensures early detection of lipohypertrophy or other complications.

How PlexusDx Supports a More Personalized Approach

Beyond injection technique, individual response to semaglutide is influenced by genetic variation in GLP-1 signaling pathways. PlexusDx's Precision Peptide Genetic Test examines key variants such as GLP1R rs6923761 and GIPR rs1800437, which may help provide context regarding how your body processes and responds to GLP-1 receptor agonists.

The genetic test reveals predispositions in peptide pathway sensitivity, not exact medication response. This information should be interpreted with a qualified healthcare provider to inform dosing strategy, site management expectations, and whether adjunctive approaches might optimize your treatment plan.

Understanding your genetic predispositions alongside proper injection technique can support a more informed conversation with your provider about personalization strategies, allowing you to establish a sustainable, well-tolerated regimen tailored to your biology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.